CRISPR Therapeutics and Vertex Pharmaceuticals announced positive interim data from the first patients in the companies’ Phase I/II clinical trials of the CRISPR/Cas9 gene-editing therapy CTX001.

The Zika virus can infect and alter cells in the human nervous system that are crucial for formation of bones and cartilage in the skull, a study found.